Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2007-01-09
2007-01-09
Yaen, Christopher H. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387300, C530S388100, C530S388220, C424S130100, C424S133100, C424S141100, C424S143100, C435S326000
Reexamination Certificate
active
10102072
ABSTRACT:
A method for the prevention or reversal of transplant rejection, or for therapy for autoimmune diseases, is provided comprising administering compounds such as monoclonal antibodies, that bind specifically to one or more preselected CD45R leukocyte antigens, including the CD45RB epitope.
REFERENCES:
patent: 4626507 (1986-12-01), Trowbridge et al.
patent: 5100899 (1992-03-01), Calne
patent: 5565491 (1996-10-01), Schieven
patent: 0449769 (1991-10-01), None
patent: WO-91/05568 (1991-05-01), None
patent: WO-93/00431 (1993-01-01), None
patent: WO-95/14230 (1995-05-01), None
patent: WO-96/32965 (1996-10-01), None
patent: WO-WO96/05204 (1996-10-01), None
Burgess et al., J of Cell Bio. 111:2129-2138, 1990.
Lazar et al. Molecular and Cellular Biology 8:1247-1252, 1988.
Rudikoff et al (Proc Natl Acad Sci USA 1982 vol. 79 p. 1979.
Poppema et al (J. Immunol. Jul. 1991; vol. 147(1): 218-223).
Streuli et al (J. Immunol. Dec. 1988; vol. 141(11): 3910-3914).
Greenspan et al (Nature Biotechnology. 1999; 7: 936-937).
“Ortho MultiCenter Transplant Study Group. A Randomized Clinical Trial of OKT3 Monoclonal Antibody for Acute Rejection of Cadeveric Transplants”,N. Eng. J. Med.,313, (Aug. 1985),337-342.
Benjamin, R..J. ,et al. ,“Induction of Tolerance by Monoclonal Antibody Therapy”,Nature,320, (1986),449-451.
Bindon, C..I. ,et al. ,“Therapeutic Potential of Monoclonal Antibodies to the Leukocyte-Common Antigen”,Transplantation,40, (1985),538-544.
Birkeland, M.L. ,et al. ,“Epitopes on CD45R (T200) Molecules Define Differentiation Antigens on Murine B and T Lymphocytes”,J. Mol. Cell. Immunol.,4, (Nov. 1988),71-85.
Brewer, Y..,et al. , “Effect of Graft Perfusion with Two CD45 Monoclonal Antibodies on Incidence of Kidney Allograft Rejection”,Lancet,(Oct. 1989),935-937.
Chatenoud, L..,et al. ,“Anti-CD3 Antibody Induces Long-Term Remission of Overt Autoimmunity in Nonobese Diabetic Mice”,Proc. Natl Acad. Sci. USA,91, (Jan. 1994),123-127.
Cosimi, A..B. ,et al. , “In Vivo Effects of Monoclonal Antibody to ICAM-1 (CD54) in Nonhuman Primates with Renal Allografts”,J. Immunol.,144, (1990),4604-4612.
Fabre, J..W. ,et al. ,“Immunosuppressive Properties of Rabbit Antibodies Against a Major Glycoprotein Restricted to Rat Leukocyte Membranes”,Transplantation,30, (Sep. 1980),167-173.
Fabre, J..W. ,et al. ,“Quantitative Serological Analysis ofa Rabbit Anti-Rat Lymphocyte Serum and Preliminary BioChemical Characterization of the Major Antigen Recognized”,Transplantation,23, (Apr. 1977),349-359.
Fahey, J..L. ,et al. ,“Status of Immune-Based Therapies in HIV Infection and Aids”,Clin. Exp. Immunol.,88, (Jan. 1992),1-5.
Hale, G..,et al. ,“Pilot Study of CAMPATH-1, a Rat Monoclonal Antibody that Fixes Human Complement, as an Immunosuppressant in Organ Transplantation”,Transplantation,42, (Sep. 1986),308-311.
Harlow, Ed.,et al. ,“Antibodies, a Laboratory Manual”,Cold Spring Harbor Laboratories,(1988),287.
Harris, W..J. ,et al. ,“Therapeutic Antibodies—The Coming of Age”,Tibtech,vol. II, Meeting Report,(Feb. 1993),42-44.
Hasan, R..,et al. ,“Evidence That Long-Term Survival of Concordant Xenografts is Achieved by Inhibition of Antispecies Antibody Production”,Transplantation,54, (Sep. 1992),408-413.
Haug, C..E. ,et al. ,“A Phase I Trial of Immunosuppression With Anti-ICAM-1 (CD54) mAb in Renal Allograft Recipients”,Transplantation,55, (Apr. 1993),766-773.
Imhof, B..,et al. ,“Lymphatic Tissues In Vivo Immune responses”,Dekker.,New York,(1991).
Isobe, M..,et al. ,“Specific Acceptance of Cardiac Allograft After treatment with Antibodies to ICAM-1 and LFA-1”,Science,255, (Feb. 1992),1125-1127.
Jolliffe, L..K. ,“Humanized Antibodies: Enhancing Therapeutic Utility Through Antibody Engineering”,Intern. Rev. Immunol.,10, (1993),241-250.
Jonker, M..,et al. ,“The Influence of OKT8F Treatment on Allograft Survival in Rhesus Monkeys”,Transplantation,41, (Apr. 1986),431-435.
Kirkman, R..L. ,et al. ,“A Randomized Prospective Trial of Anti-TAC Monoclonal Antibody in Human Renal Transplantation”,Transplantation,51, (Jan. 1991),107-113.
Kirkman, R..L. ,et al. ,“The Effect of Anti-Interleukin-2-Receptor Monoclonal Antibody on Allograft Rejection”,Transplantation,40, (Dec. 1985),719-722.
Knapp, W..,et al. , “Leucocyte Typing IV. White Cell Differentiation Antigens”, Oxford University Press, (1989),1070-1073.
Lai, R..,et al. ,“Tissue Distribution of Restricted Leukocyte Common Antigens-A Comprehensive Study with Protein-and Carbohydrate-Specific CD45R Antibodies”,Laboratory Investigation,64, See Table 2,(Jun. 1991),844-854.
Lazarovits, A..I. ,Tissue Antigens,33, (1989),275.
Lazarovits, A..I. ,et al. ,“A Monoclonal Antibody, 7G5 (CD7), Induces Modulation of Tp40 and Inhibits Proliferation in the Allogeneic and Autologous Mixed Lymphocyte Reactions”,Transplant. Proc.,20, (Dec. 1988),1253-1257.
Lazarovits, A..I. ,et al. ,“Human Mouse Chimeric CD7 Monoclonal Antibody (SDZCHH380) for the Prophylaxis of Kidney Transplant Rejection”,J. Immunol.,150, (Jun. 1993),5163-5174.
Lazarovits, A..I. ,et al. ,“Inhibition of Alloreactivity in Vitro by Monoclonal Antibodies Directed Against Restricted Isoforms of the Leukocyte-Common Antigen (CD45)”,Transplantation,,vol. 54, No. 4,(Oct. 1992),724-729.
Lazarovits, A..I. ,et al. ,“Prevention and Reversal of Renal Allograft Rejection by Antibody Against CD45RB”,Nature,,vol. 380,(Apr. 1996),pp. 717-720.
Lazarovits, A..I. ,“T Lymophocyte Activiation and CD45/45R Antibodies (Mab)”,Tissue Antigen—Histocompatibility and Immunogenetics,33, Abstract,(Feb. 1989),275.
Leonard, W..J. ,et al. ,“A Monoclonal Antibody that Appears to Recognize the Receptor for Human T-Cell Growth Factor; Partial Characterization of the Receptor”,Nature,300, (1982),267-269.
Mathieson, P..W. ,et al. ,“Monoclonal-Antibody Therapy in Systemic Vasculitis”,N. Eng. J. Med.,323, (Jul. 1990),250-254.
Nakakura, E..K. ,et al. ,“Potent And Effective Prolongation By Anti-LFA-1 Monoclonal Antibody Montherapy Of Non-Primarily Vascularized Heart Allograft Survival In Mice Without T Cell Depletion”,Transplantation,55, (Feb. 1993),412-417.
Nicolls, M..R. ,et al. ,“Induction of Long-Term Specific Tolerance to Allografts in Rats by Therapy With an Anti-CD3-Like Monoclonal Antibody”,Transplantation,55, (1993),459-468.
Nishikawa, Mitsushige.,et al. ,“Effects of Monoclonal Antibody against CD45RB on Peripheral Blood Mononuclear Cell Proliferation and on HLA-DR and Adhesion Molecule Expression on Thyrocytes of Patients with Autoimmune Thyroid Disease”,Thyroid,vol. 5. No. 4,(1995),pp. 265-272.
Ogasa, N.,et al. ,“Altered Expression of Cytokine Genes by CD45RB Monoclonal Antibody in Renal Allograft Rejection”,Transplantation Proceedings,27, No. 1, (Feb. 1995),398.
Ozcay, N..,et al. ,“Prevention of heart allograft rejection by monoclonal antibody to CD45RB”,Turk. J. Surg.,vol. 11, No. 6,(1995),pp. 372-376.
Pearson, T..C. ,et al. ,“Lymphocyte Changes Associated with Prolongation of Cardiac Allograft Survival in Adult Mice Using Anti-CD4 Monoclonal Antibody”,Clin. Exp. Immunol.,92, (1993),211-217.
Pearson, T..C. ,et al. ,“The Assessment of Transplantation Tolerance Induced by Anti-CD4 Monoclonal Antibody in the Murine Model”,Transplantation,55, (Feb. 1993),361-367.
Perico, N..,et al. ,“Toward Novel Antirejection Strategies: In Vivo Immunosuppressive Properties of CTLA4lg”,Kidney International,47, (1995),241-246.
Poppema, S..,et al. ,“Antobody MT3 is Reactive with a Novel Exon B-Associated 190-Da Sialic Acid-Dependent Epitope of the Leukocyte Common Antigen Complex”,The Journal of Immunology,147, No. 1,(Jul. 1991),218-223.
P
Lazarovits Andrew I.
Poppema Sibrand
Alimunne, L.L.C.
Schwegman Lundberg Woessner & Kluth P.A.
Yaen Christopher H.
LandOfFree
Use of anti-CD45 leukocyte antigen antibodies for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of anti-CD45 leukocyte antigen antibodies for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of anti-CD45 leukocyte antigen antibodies for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3722704